Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2870-2878

  Crown, John P ^a   Diéras, Véronique ^b   Staroslawska, Elzbieta ^f   Yardley, Denise A ^h   Bachelot, Thomas ^c   Davidson, Neville ⁱ   Wildiers, Hans ^j   Fasching, Peter A ^k   Capitain, Olivier ^d   Ramos, Manuel ⁿ   Greil, Richard ^o   Cognetti, Francesco ^p   Fountzilas, George ^r   Blasinska Morawiec, Maria ^g   Liedtke, Cornelia ^l   Kreienberg, Rolf ^m   Miller, Wilson H ^s   Tassell, Vanessa ^q   Huang, Xin ^q   Paolini, Jolanda ^q   Kern, Kenneth A ^q   Romieu, Gilles ^e   more..

^a Ireland Cooperative Oncology Research Group ICORG   (Ireland)

^b INSTITUT CURIE   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE PAUL PAPIN   (France)

^e CENTRE VAL D AURELLE   (France)

^f Centrum Onkologii Ziemi Lubelskiej   (Poland)

^g M Madurowicza I Oddzia Chorob   (Poland)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

ⁱ BROOMFIELD HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^l UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ Centro Oncologico de Galicia   (Spain)

^o PARACELSUS MEDICAL UNIVERSITY   (Austria)

^p REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^q PFIZER INC   (United States)

^r ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^s MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; SUNITINIB; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTENTION TO TREAT ANALYSIS; LACRIMATION DISORDER; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR GROWTH; UPPER ABDOMINAL PAIN; VOMITING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; METASTASIS; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INDOLES; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PYRROLES; YOUNG ADULT;

EID: 84884126500     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.3391     Document Type: Article

References (35)

1. Roche: XELODA (capecitabine) prescribing information, 2006. http://www.gene.com/gene/products/information/xeloda/pdf/pi.pdf
2. Oostendorp LJ, Stalmeier PF, Donders AR, et al: Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review. Lancet Oncol 12:1053-1061, 2011
3. Folkman J: Tumor angiogenesis: Therapeutic complications. N Engl J Med 285:1182-1186, 1971
4. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
5. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
6. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
7. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
8. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20: 757-766, 2003
9. Banerjee S, Dowsett M, Ashworth A, et al: Mechanisms of disease: Angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4:536-550, 2007
10. Paulsson J, Sjöblom T, Micke P, et al: Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175:334-341, 2009
11. Tsuda H, Morita D, Kimura M, et al: Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 96:48-53, 2005
12. Goswami S, Sahai E, Wyckoff JB, et al: Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 65:5278-5283, 2005
13. Burstein HJ, Elias AD, Rugo HS, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008
14. Escudier B, Roigas J, Gillessen S, et al: Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokinerefractory metastatic renal cell carcinoma. J Clin Oncol 27:4068-4075, 2009
15. Barrios CH, Hernandez-Barajas D, Brown MP, et al: Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118:1252-1259, 2012
16. George S, Blay JY, Casali PG, et al: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959-1968, 2009
17. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
18. Abrams TJ, Murray LJ, Pesenti E, et al: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021, 2003
19. Sweeney CJ, Chiorean EG, Verschraegen CF, et al: A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 28:4513-4520, 2010
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Pfizer: Sutent (sunitinib malate) prescribing information, 2012. http://www.pfizer.com/files/products/uspi-sutent.pdf
22. Barrios CH, Liu MC, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010
23. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005
24. Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007
25. Brufsky AM, Hurvitz S, Perez E, et al: RIBBON-2: A randomized, double-blind, placebocontrolled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286-4293, 2011
26. Sparano JA, Vrdoljak E, Rixe O, et al: Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28:3256-3263, 2010
27. Curigliano G, Pivot X, Cortes J, et al: A randomized phase II study of sunitinib vs standard of care for patients with previously treated advanced triple-negative breast cancer. Presented at the 33rd San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-10, 2010 (poster P6-12-02)
28. Bergh J, Bondarenko IM, Lichinitser MR, et al: First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. J Clin Oncol 30:921-929, 2012
29. Robert NJ, Saleh MN, Paul D, et al: Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 11:82-92, 2011
30. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
31. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
32. Paèz-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
33. Loges S, Mazzone M, Hohensinner P, et al: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15:167-170, 2009
34. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
35. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047, 2000